Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Halozyme Therapeutic (HALO)
Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,277,316
  • Shares Outstanding, K 132,098
  • Annual Sales, $ 660,120 K
  • Annual Income, $ 202,130 K
  • 60-Month Beta 1.25
  • Price/Sales 8.03
  • Price/Cash Flow 15.48
  • Price/Book 21.26
Trade HALO with:

Options Overview Details

View History
  • Implied Volatility 38.63% ( +0.35%)
  • Historical Volatility 45.14%
  • IV Percentile 33%
  • IV Rank 47.58%
  • IV High 59.73% on 04/21/23
  • IV Low 19.48% on 03/13/23
  • Put/Call Vol Ratio 0.30
  • Today's Volume 61
  • Volume Avg (30-Day) 413
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 11,758
  • Open Int (30-Day) 12,145

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.73
  • Number of Estimates 6
  • High Estimate 0.81
  • Low Estimate 0.68
  • Prior Year 0.44
  • Growth Rate Est. (year over year) +65.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.87 +9.76%
on 11/13/23
41.09 -1.51%
on 11/27/23
+3.22 (+8.64%)
since 11/10/23
3-Month
32.83 +23.27%
on 10/25/23
41.61 -2.74%
on 09/14/23
+2.97 (+7.92%)
since 09/11/23
52-Week
29.85 +35.58%
on 05/09/23
59.40 -31.87%
on 12/13/22
-16.46 (-28.91%)
since 12/09/22

Most Recent Stories

More News
Halozyme Therapeutics: Q3 Earnings Snapshot

Halozyme Therapeutics: Q3 Earnings Snapshot

HALO : 40.49 (+1.35%)
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from...

HALO : 40.49 (+1.35%)
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") will present the positive results of a clinical study demonstrating subcutaneous...

HALO : 40.49 (+1.35%)
3 Biotech Stocks Showing Promising Returns for October

Technological advancements and the growing investment in developing healthcare infrastructures are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech...

BMRN : 93.40 (+0.49%)
HALO : 40.49 (+1.35%)
UTHR : 243.28 (+0.67%)
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's...

HALO : 40.49 (+1.35%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 40.49 (+1.35%)
KNSA : 17.01 (-1.51%)
ACAD : 21.14 (+0.76%)
HRMY : 31.00 (+0.24%)
AMPH : 57.05 (+0.49%)
INCY : 56.91 (+4.04%)
AGEN : 0.6827 (-8.55%)
NVS : 97.05 (+0.78%)
PFE : 28.53 (-0.87%)
SGEN : 221.00 (+0.92%)
MRK : 104.00 (+0.24%)
RXDX : 199.92 (+0.09%)
Halozyme Therapeutics: Q2 Earnings Snapshot

Halozyme Therapeutics: Q2 Earnings Snapshot

HALO : 40.49 (+1.35%)
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second...

HALO : 40.49 (+1.35%)
Halozyme To Report Second Quarter 2023 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results...

HALO : 40.49 (+1.35%)
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx reported positive topline data from the ADHERE study...

HALO : 40.49 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 42.45
2nd Resistance Point 41.76
1st Resistance Point 40.85
Last Price 40.49
1st Support Level 39.26
2nd Support Level 38.57
3rd Support Level 37.66

See More

52-Week High 59.40
Fibonacci 61.8% 48.11
Fibonacci 50% 44.63
Fibonacci 38.2% 41.14
Last Price 40.49
52-Week Low 29.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar